Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 3 1Phase 1 1

Status

Active not recruiting 5Recruiting 4Completed 4Terminated 3Withdrawn 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Lymphoma 1Leukemia 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × acalabrutinib × Clear all
NCT05205252 2023-08-15

ARIA

Ipsen

Phase 1/2 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

NCT04961801 2022-03-08

Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia

Milton S. Hershey Medical Center

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡